Close Menu

CHICAGO (GenomeWeb) – Cancer informatics and precision medicine company Tempus said today that it has landed $200 million in a Series F investment round. This new round brings the four-year-old firm's total venture capital to $520 million and valuation to $3.1 billion.

Series F investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and T. Rowe Price. With the investment, Novo Holdings Director Robert Ghenchev has joined the Tempus board of directors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.